2.4832
price up icon7.73%   0.1782
after-market Handel nachbörslich: 2.56 0.0768 +3.09%
loading
Schlusskurs vom Vortag:
$2.305
Offen:
$2.2586
24-Stunden-Volumen:
30,811
Relative Volume:
2.63
Marktkapitalisierung:
$26.01M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-3.15M
KGV:
-12.00
EPS:
-0.2069
Netto-Cashflow:
$-2.23M
1W Leistung:
-3.00%
1M Leistung:
+30.43%
6M Leistung:
+20.84%
1J Leistung:
-38.69%
1-Tages-Spanne:
Value
$2.25
$2.58
1-Wochen-Bereich:
Value
$2.13
$2.58
52-Wochen-Spanne:
Value
$1.20
$5.50

Cytomed Therapeutics Ltd Stock (GDTC) Company Profile

Name
Firmenname
Cytomed Therapeutics Ltd
Name
Telefon
-
Name
Adresse
-
Name
Mitarbeiter
34
Name
Twitter
Name
Nächster Verdiensttermin
Name
Neueste SEC-Einreichungen
Name
GDTC's Discussions on Twitter

Cytomed Therapeutics Ltd Aktie (GDTC) Neueste Nachrichten

pulisher
Oct 23, 2024

Discovering Penny Stocks On US Exchanges: 3 Picks Under $100M Market Cap - Simply Wall St

Oct 23, 2024
pulisher
Oct 16, 2024

Osteopore Partners with CytoMed in Regenerative Medicine - TipRanks

Oct 16, 2024
pulisher
Oct 16, 2024

Osteopore partners with NASDAQ-listed CytoMed to advance MSC-powered regeneration - Biotech Dispatch

Oct 16, 2024
pulisher
Oct 08, 2024

CytoMed begins clinical trial for innovative cancer therapy - Investing.com

Oct 08, 2024
pulisher
Oct 07, 2024

CytoMed Therapeutics completes cash acquisition of Cord Blood Banking Licence and Assets expanding CytoMed’s strategy to cord blood-derived biologics through subsidiary, LongevityBank - Marketscreener.com

Oct 07, 2024
pulisher
Oct 07, 2024

Cytomed Therapeutics announces NMRC co-funding support for ANGELICA trial - TipRanks

Oct 07, 2024
pulisher
Oct 07, 2024

CytoMed Launches Innovative CAR-T Cell Trial - TipRanks

Oct 07, 2024
pulisher
Oct 07, 2024

CytoMed begins clinical trial for innovative cancer therapy By Investing.com - Investing.com South Africa

Oct 07, 2024
pulisher
Oct 07, 2024

CytoMed Therapeutics’ first-in-human Phase I ANGELICA - GlobeNewswire

Oct 07, 2024
pulisher
Oct 07, 2024

CytoMed Therapeutics’ first-in-human Phase I ANGELICA clinical trial using its patented donor allogeneic chimeric antigen receptor T cell (CAR-T cell) against blood and solid tumors received co-funding support from the NMRC Clinical Trial Grant - StockTitan

Oct 07, 2024
pulisher
Oct 04, 2024

CytoMed Acquires Cord Blood Assets, Eyes Regenerative Medicine - Yahoo Finance

Oct 04, 2024
pulisher
Oct 03, 2024

CytoMed Therapeutics completes cash acquisition of Cord Blood Banking Licence and Assets expanding CytoMed's strategy to cord blood-derived biologics through subsidiary, LongevityBank - The Manila Times

Oct 03, 2024
pulisher
Oct 03, 2024

CytoMed Therapeutics completes cash acquisition of Cord - GlobeNewswire

Oct 03, 2024
pulisher
Sep 30, 2024

GDTCCytoMed Therapeutics Limited Ordinary Shares Latest Stock News & Market Updates - StockTitan

Sep 30, 2024
pulisher
Sep 30, 2024

CYTOMED THERAPEUTICS : AND SUBSIDIARIES UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Form 6 K - Marketscreener.com

Sep 30, 2024
pulisher
Sep 30, 2024

CytoMed Therapeutics Reports Six Months Ended June 30, 2024 - GlobeNewswire

Sep 30, 2024
pulisher
Sep 30, 2024

CytoMed Therapeutics Reports Six Months Ended June 30, 2024 Financial Results and Provides Clinical and Corporate Updates - Yahoo Finance

Sep 30, 2024
pulisher
Sep 25, 2024

Presenting on the Emerging Growth Conference 75 Day 2 on September 26 - GlobeNewswire

Sep 25, 2024
pulisher
Aug 25, 2024

CytoMed Therapeutics Limited acquired the licence and certain assets of Cellsafe International Sdn Bhd from Cellsafe Biotech Group for MYR 2.3 million. - Marketscreener.com

Aug 25, 2024
pulisher
Aug 20, 2024

Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now - GlobeNewswire

Aug 20, 2024
pulisher
Jul 25, 2024

CytoMed Therapeutics (NASDAQ:GDTC) Trading Down 2% - Defense World

Jul 25, 2024
pulisher
Jul 17, 2024

CytoMed Therapeutics Ltd (GDTC) Stock: A Comprehensive 52-Week Review - The InvestChronicle

Jul 17, 2024
pulisher
Jul 17, 2024

CytoMed Therapeutics Acquires Cord Blood Banking Licence - GlobeNewswire

Jul 17, 2024
pulisher
Jul 17, 2024

CytoMed Therapeutics Acquires Cord Blood Banking Licence and Assets to Entrench Its Strategy in Allogeneic, Off-the-shelf Donor-derived Gamma Delta (γδ) T Cells Technology for Solid and Liquid Cancers - GlobeNewswire

Jul 17, 2024
pulisher
Jul 17, 2024

Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now - GlobeNewswire Inc.

Jul 17, 2024
pulisher
Jun 27, 2024

CytoMed Therapeutics Limited Announces Board and Audit Committee Changes - Marketscreener.com

Jun 27, 2024
pulisher
Jun 20, 2024

CytoMed Therapeutics Limited Announces Collaboration with MD Anderson Cancer Center to Advance Allogeneic Off ... - Quantisnow

Jun 20, 2024
pulisher
Jun 20, 2024

CytoMed Therapeutics to Ring Nasdaq Closing Bell - Quantisnow

Jun 20, 2024
pulisher
Jun 20, 2024

CytoMed Therapeutics Limited Announces Closing of US$9,649,476 Firm Commitment Initial Public Offering - Quantisnow

Jun 20, 2024
pulisher
Jun 20, 2024

CytoMed Therapeutics to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference - Quantisnow

Jun 20, 2024
pulisher
Jun 20, 2024

CytoMed Therapeutics Announces China Research Collaboration to Enhance its Allogeneic CAR γδ T In Vivo ... - Quantisnow

Jun 20, 2024
pulisher
Jun 20, 2024

A*STAR Spinoff CytoMed Therapeutics Announce a Patent for its Licensed CAR-Gamma Delta T Cell Technology Has ... - Quantisnow

Jun 20, 2024
pulisher
Jun 20, 2024

CytoMed Therapeutics : Board re organization Form 6 K - Marketscreener.com

Jun 20, 2024
pulisher
Jun 12, 2024

Natural Alternatives International (NASDAQ:NAII) Receives New Coverage from Analysts at StockNews.com - Defense World

Jun 12, 2024
pulisher
Jun 12, 2024

Viridian Therapeutics (NASDAQ:VRDN) Receives New Coverage from Analysts at Wolfe Research - Defense World

Jun 12, 2024
pulisher
Jun 11, 2024

Anti-aging Therapeutics Market Size, Scope, Growth and Forecast to 2031 - InsightAce Analytic

Jun 11, 2024
pulisher
May 24, 2024

CytoMed Therapeutics : Annual Shareholders MeetingForm 6-K - Marketscreener.com

May 24, 2024
pulisher
Mar 20, 2024

CytoMed Diversifies into Regenerative Medicine after Research Collaboration with Singapore's Sengkang General Hospital to Test Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Regeneration - Yahoo Finance

Mar 20, 2024
pulisher
Mar 18, 2024

CytoMed Therapeutics to Launch Complimentary Cell Banking for Qualified Shareholders for Future Precision Therapies - Marketscreener.com

Mar 18, 2024
pulisher
Mar 04, 2024

CytoMed Therapeutics Limited Announces Research - GlobeNewswire

Mar 04, 2024
pulisher
Feb 07, 2024

Healthcare Stocks Moving Wednesday: OGEN, FEMY, JSPR, ABEO, GDTC, CING, HUMA, NEXI - InvestorsObserver

Feb 07, 2024
pulisher
Jan 29, 2024

Malaysian Patent Granted for CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Technology - Yahoo Finance

Jan 29, 2024
pulisher
Jan 23, 2024

GDTC Stock Price and Chart — NASDAQ:GDTC - TradingView

Jan 23, 2024
pulisher
Dec 05, 2023

CytoMed Therapeutics Signs HOA and MOU to Advance Research on Allogeneic Gamma Delta T Cell Technology - PR Newswire

Dec 05, 2023
pulisher
Nov 17, 2023

CytoMed Therapeutics Reports First Half 2023 Financial Report and Provides Corporate Update - PR Newswire

Nov 17, 2023
pulisher
Oct 24, 2023

Cytomed Therapeutics Limited (GDTC-Q) QuotePress Release - The Globe and Mail

Oct 24, 2023
pulisher
Sep 25, 2023

Chinese Patent Granted for CytoMed Therapeutics' Licensed iPSC-Based Technology - PR Newswire

Sep 25, 2023
pulisher
Aug 16, 2023

CytoMed Therapeutics Announces China Research Collaboration to Enhance its Allogeneic CAR γδ T In Vivo Persistency - 팜뉴스

Aug 16, 2023
pulisher
Jul 25, 2023

Novel T-Cell Immunotherapies Market Share, Size, Growth and Forecast to 2031 - InsightAce Analytic

Jul 25, 2023
pulisher
Jul 11, 2023

Why Is CytoMed Therapeutics (GDTC) Stock Up 157% Today? - InvestorPlace

Jul 11, 2023
pulisher
Jul 06, 2023

A*STAR Spinoff CytoMed Therapeutics Announce a Patent for its Licensed CAR-Gamma Delta T Cell Technology Has Been Granted in the US - PR Newswire

Jul 06, 2023

Finanzdaten der Cytomed Therapeutics Ltd-Aktie (GDTC)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$19.96
price up icon 5.11%
$75.75
price down icon 0.50%
$376.80
price up icon 0.74%
$53.54
price down icon 2.00%
$207.25
price up icon 1.49%
$108.97
price down icon 2.25%
Kapitalisierung:     |  Volumen (24h):